Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effect of the MIROKI Companion Robot on Anxiety in Pediatric Radiotherapy (KOKORO01)

Pediatric radiotherapy is an anxiety-provoking situation that can, on one hand, impair the child's cooperation and require sedation, and on the other hand,burden the care pathway by generating significant anxiety in both the child and their parents. Companion robots represent an innovative avenue for patient support, but they have never been evaluated in the context of radiotherapy. This study examines the effect of MIROKI, the first social robot capable of communication through a Large Multimodal Model (LMM), on children's state anxiety during radiotherapy. An experimental single-case design (SCED) will compare phases with and without the robot (withdrawal/reversal), both in the waiting room and in the irradiation bunker. The primary outcome variable is anxiety, assessed in several ways: through questionnaires at the beginning and end of treatment; through an objective measure of cardiac activity (heart rate in bpm) during the radiotherapy session, with or without the MIROKI robot; and through an observational grid assessing the child's behavior. The intensive repeated measure (bpm) constitutes the preferred variable in this SCED design, while behavioral observation and anxiety questionnaires will support interpretation. The results could pave the way for reducing sedation and improving the overall care pathway in pediatric radiotherapy.

Studieöversikt

Status

Har inte rekryterat ännu

Studietyp

Observationell

Inskrivning (Beräknad)

6

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Herault
      • Montpellier, Herault, Frankrike, 34298
        • Julien Welmant

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Ja

Testmetod

Sannolikhetsprov

Studera befolkning

Participants will be recruited from the pediatric radiotherapy unit at Montpellier Cancer Institute (ICM).During the initial consultation to initiate radiotherapy treatment at ICM, the investigator physician will present the KOKORO-01 study. They will answer all questions regarding its procedures and will provide the parents or legal representative with the information sheet and consent form. Parents or the legal representative will have at least one week to consider participation, during which they may ask any questions they wish.

Beskrivning

Inclusion Criteria:

  1. Children aged 4 to 18 years, distributed across the following age groups: 4-7 years, 8-12 years, and 13-18 years.
  2. Child with an indication for radiotherapy treatment at ICM.
  3. Child who speaks French.
  4. Child accompanied by a parent or legal guardian who agrees to participate in the study and provide consent.
  5. Child covered by the French national health insurance system.

Exclusion Criteria:

6. Child with a diagnosed neurodevelopmental disorder as a comorbidity. 7. Child with postoperative cognitive sequelae that make interaction during care difficult (e.g., language impairment). 8. Total body irradiation. 9. Child under legal protection, unable to express assent, or presenting major difficulties in understanding the study information. Parent Inclusion Criteria

  1. Parent of a child enrolled in the study.
  2. Able to speak French.
  3. Willing to participate in the study. Parent Exclusion Criteria

1. Parents or legal representatives under legal protection, or presenting an inability to consent or to understand the study information, making it impossible to provide free and informed consent for the minor's participation.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
To evaluate the immediate intra-individual effect of MIROKI on a physiological marker of anxiety in children undergoing radiotherapy.
Tidsram: During the treatment, across the 6 radiotherapy sessions
The child's anxiety level measured through an objective assessment of heart rate (bpm sensor).
During the treatment, across the 6 radiotherapy sessions

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Evaluate the immediate intra-individual effect of MIROKI in children on: Psychological distress level
Tidsram: administered before the start of treatment and after completion of treatment
Distress questionnaire (PedsQL 3.0 Cancer Module score, Varni et al.)
administered before the start of treatment and after completion of treatment
Evaluate the immediate intra-individual effect of MIROKI in children on development of attachment and reassurance
Tidsram: Before, during, and after treatment
Daily distress VAS (Peds-DTRS score, Patel et al., 2011, 2021) and standardized real-time observation using an observational grid.
Before, during, and after treatment
Evaluate the satisfaction with care (radiotherapy at ICM) at the end of treatment
Tidsram: At the end of treatment
Post-treatment interview (thematic and lexico-metric analysis).
At the end of treatment
Evaluate the impact of MIROKI on the radiotherapy process: Setup time during sessions in the radiotherapy room
Tidsram: From the beginning to the end of the treatment course
From the beginning to the end of the treatment course
Evaluate the impact of MIROKI on parents: - Anxiety level - Satisfaction with care at the end of treatment - Experience of the radiotherapy process at the end of treatment
Tidsram: Before the start , during and after the treatment,
  • Anxiety score (GAD-7, Spitzer et al., 2006)
  • Parent-child relationship quality score (CPRS, Pianta et al., 1992)

During treatment:

- Daily anxiety VAS (daily DT score, Leclair et al., 2016; NCCN, 2025)

After treatment:

- Assessment of the radiotherapy experience and satisfaction with care with the robot, using the parent interview grid

Before the start , during and after the treatment,

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Julien, Welmant, ICM Co. Ltd.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juli 2026

Primärt slutförande (Beräknad)

1 juli 2027

Avslutad studie (Beräknad)

1 juli 2027

Studieregistreringsdatum

Först inskickad

9 juni 2026

Först inskickad som uppfyllde QC-kriterierna

9 juni 2026

Första postat (Faktisk)

12 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • PROICM 2026-01 KOK

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

All data will be available after publication of the results in peer-reviewed revues, and in national and international meetings. It includes all de-identified participants' data, the study protocol, the statistical analysis plan and the clinical study report. The corresponding author will provide data and datasets generated and/or analyzed during the study upon reasonable request.

Tidsram för IPD-delning

Access to study data upon written detailed request sent to ICM, from 6 months until 5 years after publication of summary data.

Kriterier för IPD Sharing Access

The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from ICM for personal access, and data will only be transferred after signing of a data access agreement.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera